A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

References

• Campbell S, Diaz-Recasens J, Griffin D R, Cohen-Overbeek T E, Pearce J M, Willson K, Teague M J. New Doppler technique for assessing uteroplacental blood flow. Lancet 1983; 1: 675–677
   PubMed Web of Science ®Google Scholar
• Harrington K F, Campbell S, Bewley S, Bower S. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991; 42(Suppl)S14–20
   PubMed Web of Science ®Google Scholar
• Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1993; 100: 989–994
   PubMedGoogle Scholar
• Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the uterine arteries: The importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996; 7: 182–188
   PubMed Web of Science ®Google Scholar
• Dekker G A, Sibai B M. Etiology and pathogenesis of preeclampsia: Current concepts. Am J Obstet Gynecol 1998; 179: 1359–1375
   PubMed Web of Science ®Google Scholar
• Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides K H. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000; 96: 559–564
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Yu C K, Bindra R, Pandis G, Nicolaides K H. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441–449
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Yu C K, Nicolaides K H. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 383–396
   PubMed Web of Science ®Google Scholar
• Roberts J M, Taylor R N, Musci T J, Rodgers G M, Hubel C A, McLaughlin M K. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200–1204
   PubMed Web of Science ®Google Scholar
• Redman C W, Sacks G P, Sargent I L. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499–506
   PubMed Web of Science ®Google Scholar
• Poston L, Chappell L C. Is oxidative stress involved in the aetiology of pre-eclampsia?. Acta Paediatr Suppl 2001; 90: 3–5
   PubMedGoogle Scholar
• Roberts J M, Lain K Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002; 23: 359–372
   PubMed Web of Science ®Google Scholar
• Johnson M R, Anim-Nyame N, Johnson P, Sooranna S R, Steer P J. Does endothelial cell activation occur with intrauterine growth restriction?. BJOG 2002; 109: 836–839
   PubMed Web of Science ®Google Scholar
• Redman C W, Sargent I L. Latest advances in understanding preeclampsia. Science 2005; 308: 1592–1594
   PubMed Web of Science ®Google Scholar
• Ness R B, Sibai B M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006; 195: 40–49
   PubMed Web of Science ®Google Scholar
• Maynard S E, Min J Y, Merchan J, Lim K H, Li J, Mondal S, Libermann T A, Morgan J P, Sellke F W, Stillman I E, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant J F, Pignon M R, Noel A, Schaaps J P, Cabrol D, Frankenne F, Foidart J M. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563
   PubMed Web of Science ®Google Scholar
• Levine R J, Maynard S E, Qian C, Lim K H, England L J, Yu K F, Schisterman E F, Thadhani R, Sachs B P, Epstein F H, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee K Y, Goncalves L F, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541–1547
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim Y M, Kim G J, Kim M R, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18
   PubMed Web of Science ®Google Scholar
• McKeeman G C, Ardill J E, Caldwell C M, Hunter A J, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240–1246
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers R W, Larkin R W, Gilmour C, Bodnar L M, Crombleholme W R, Ness R B, Roberts J M, Hubel C A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895–4903
   PubMed Web of Science ®Google Scholar
• Staff A C, Braekke K, Harsem N K, Lyberg T, Holthe M R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33–39
   PubMed Web of Science ®Google Scholar
• Robinson C J, Johnson D D, Chang E Y, Armstrong D M, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195: 255–259
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y M, Bdolah Y, Lim K H, Yuan H T, Libermann T A, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649
   PubMed Web of Science ®Google Scholar
• Levine R J, Lam C, Qian C, Yu K F, Maynard S E, Sachs B P, Sibai B M, Epstein F H, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005
   PubMed Web of Science ®Google Scholar
• Torry D S, Wang H S, Wang T H, Caudle M R, Torry R J. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539–1544
   PubMed Web of Science ®Google Scholar
• Tidwell S C, Ho H N, Chiu W H, Torry R J, Torry D S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272
   PubMed Web of Science ®Google Scholar
• Tjoa M L, van Vugt J M, Mulders M A, Schutgens R B, Oudejans C B, van Wijk I J. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98: 600–607
   PubMed Web of Science ®Google Scholar
• Chappell L C, Seed P T, Briley A, Kelly F J, Hunt B J, Charnock-Jones D S, Mallet A I, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127–136
   PubMed Web of Science ®Google Scholar
• Taylor R N, Grimwood J, Taylor R S, McMaster M T, Fisher S J, North R A. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177–182
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter W P, Wolf M, Levine R J, Taylor R N, Sukhatme V P, Ecker J, Karumanchi S A. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–775
   PubMed Web of Science ®Google Scholar
• Krauss T, Pauer H U, Augustin H G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101–111
   PubMed Web of Science ®Google Scholar
• Levine R J, Thadhani R, Qian C, Lam C, Lim K H, Yu K F, Blink A L, Sachs B P, Epstein F H, Sibai B M, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293: 77–85
   PubMed Web of Science ®Google Scholar
• Parra M, Rodrigo R, Barja P, Bosco C, Fernandez V, Munoz H, Soto-Chacon E. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005; 193: 1486–1491
   PubMed Web of Science ®Google Scholar
• Barbara N P, Wrana J L, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274: 584–594
   PubMed Web of Science ®Google Scholar
• Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez L A, Langa C, Fabra A, Letarte M, et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996; 133: 1109–1121
   PubMed Web of Science ®Google Scholar
• Letamendia A, Lastres P, Botella L M, Raab U, Langa C, Velasco B, Attisano L, Bernabeu C. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 1998; 273: 33 011–33 019
   Google Scholar
• Goumans M J, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21: 1743–1753
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra M R, Coral S, Natali P G, Maio M. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1–7
   PubMed Web of Science ®Google Scholar
• Gonzalez R P, Gomez R M, Castro R S, Nien J K, Merino P O, Etchegaray A B, Carstens M R, Medina L H, Viviani P G, Rojas I T. [A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000]. Rev Med Chil 2004; 132: 1155–1165
   PubMed Web of Science ®Google Scholar
• Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. Springer-Verlag, New York 2000
   Google Scholar
• Sen A, Srivastava M. Unequal variances. Regression analysis theory, methods, and applications, A Sen, M Srivastava. Springer, New York 1990; 111–131
   Google Scholar
• Huber P J. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, Berkeley, CAUSA 1967; 221–223
   Google Scholar
• White H. Maximum likelihood estimation of misspecified models. Econometrica 1982; 50: 1–25
   Web of Science ®Google Scholar
• Liang K Y, Zeger S L. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13–22
   Web of Science ®Google Scholar
• Carroll RJ, Wang S, Simpson DG, Stromberg AJ, Ruppert D. The sandwich (robust covariance matrix) estimator; 1998. Available at: http://www.stat.tamu.edu/ftp/pub/rjcarroll/sandwich.pdf (accessed December 2007)
   Google Scholar
• Efron B, Tibshirani R. An introduction to the bootstrap. Chapman Hall, New York 2003
   Google Scholar
• Wulff C, Wilson H, Dickson S E, Wiegand S J, Fraser H M. Hemochorial placentation in the primate: Expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod 2002; 66: 802–812
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389–395
   PubMed Web of Science ®Google Scholar
• Yancopoulos G D, Davis S, Gale N W, Rudge J S, Wiegand S J, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–248
   PubMed Web of Science ®Google Scholar
• Mayhew T M. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta 2002; 23: 742–750
   PubMed Web of Science ®Google Scholar
• Gale N W, Yancopoulos G D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13: 1055–1066
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001: RE21
   PubMedGoogle Scholar
• Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004; 25: 581–611
   PubMed Web of Science ®Google Scholar
• Clark D E, Smith S K, He Y, Day K A, Licence D R, Corps A N, Lammoglia R, Charnock-Jones D S. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540–1548
   PubMed Web of Science ®Google Scholar
• Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marme D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4: 143–154
   PubMedGoogle Scholar
• Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: The elusive preeclampsia factor discovered?. J Clin Invest 2003; 111: 600–602
   PubMed Web of Science ®Google Scholar
• Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356–1370
   PubMed Web of Science ®Google Scholar
• Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936–943
   PubMed Web of Science ®Google Scholar
• Beck H, Acker T, Puschel A W, Fujisawa H, Carmeliet P, Plate K H. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol 2002; 61: 339–350
   PubMedGoogle Scholar
• Iyer S, Acharya K R. Role of placenta growth factor in cardiovascular health. Trends Cardiovasc Med 2002; 12: 128–134
   PubMed Web of Science ®Google Scholar
• Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy J A, Hooper A, Priller J, De Klerck B, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831–840
   PubMed Web of Science ®Google Scholar
• Shore V H, Wang T H, Wang C L, Torry R J, Caudle M R, Torry D S. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657–665
   PubMed Web of Science ®Google Scholar
• Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838–4845
   PubMed Web of Science ®Google Scholar
• Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141: 1925–1933
   PubMed Web of Science ®Google Scholar
• Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Latarte M, Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg–Gly–Asp-containing surface antigen. Eur J Immunol 1992; 22: 393–397
   PubMed Web of Science ®Google Scholar
• O'Connell P J, McKenzie A, Fisicaro N, Rockman S P, Pearse M J, d'Apice A J. Endoglin: A 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol 1992; 90: 154–159
   PubMedGoogle Scholar
• Buhring H J, Muller C A, Letarte M, Gougos A, Saalmuller A, van Agthoven A J, Busch F N. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 1991; 5: 841–847
   PubMed Web of Science ®Google Scholar
• Gougos A, St Jacques S, Greaves A, O'Connell P J, d'Apice A J, Buhring H J, Bernabeu C, Van Mourik J A, Letarte M. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992; 4: 83–92
   PubMed Web of Science ®Google Scholar
• St Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 1994; 134: 2645–2657
   PubMedGoogle Scholar
• Rokhlin O W, Cohen M B, Kubagawa H, Letarte M, Cooper M D. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 1995; 154: 4456–4465
   PubMed Web of Science ®Google Scholar
• Calabro L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Sigalotti L, Altomonte M, Musolino C, Maio M. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003; 194: 171–175
   PubMed Web of Science ®Google Scholar
• Diggle P, Heagerty P, Liang K Y, Zeger S L. Analysis of longitudinal data. Oxford University Press, Oxford 2002; 1–21
   Google Scholar
• Pahwa P, Blair T. Statistical model for the analysis of longitudinal data; 2002. Available at: http://www.cacr.ca/news/2002/0204pahwa.htm (accessed December 2007)
   Google Scholar
• Diggle P, Heagerty P, Liang K Y, Zeger S L. Missing values in longitudinal data. Analysis of longitudinal data. Oxford University Press, Oxford 2002; 282–318
   Google Scholar
• Espinoza J, Chaiworapongsa T, Romero R, Kim Y M, Kim G J, Nien J K, Kusanovic J P, Erez O, Bujold E, Goncalves L F, et al. Unexplained fetal death: Another anti-angiogenic state. J Matern Fetal Neonatal Med 2007; 20: 495–507
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien J K, Kusanovic J P, Richani K, Gomez R, Kim C J, Mittali P, Gotsh F, Erez O, et al. A role for the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006; 19: 607–613
   PubMed Web of Science ®Google Scholar
• Bersinger N A, Odegard R A. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37–45
   PubMed Web of Science ®Google Scholar
• Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201–207
   PubMed Web of Science ®Google Scholar
• Signore C, Mills J L, Qian C, Yu K, Lam C, Epstein F H, Karumanchi S A, Levine R J. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006; 108: 338–344
   PubMed Web of Science ®Google Scholar
• Espinoza J, Nien J K, Kusanovic J P, Richani K, Gomez R, Kim C J, Mittal P, Chaiworapongsa T, Romero R. A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome). Am J Obstet Gynecol 2005; 193: S134
   Google Scholar
• Rana S, Venkatesha S, DePaepe M, Chien E K, Paglia M, Karumanchi S A. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol 2007; 109: 549–552
   PubMed Web of Science ®Google Scholar
• Stepan H, Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006; 354: 1857–1858
   PubMed Web of Science ®Google Scholar